Bovine-Derived Grafts (Pericardium & Dermis)
Bovine pericardium and bovine dermis are different xenograft materials. Processing, crosslinking, thickness, preservation and the intended implantation site matter more than the animal source alone. Clinical experience with one preparation does not establish the performance or labeling of another.
The reviewed Peri-Guard instructions describe a glutaraldehyde-crosslinked bovine pericardial patch for specified cardiovascular and thoracic repairs; they do not list Peyronie's grafting, urethroplasty or bladder augmentation as indications. The published urologic uses are outside those labeled indications. The US FDA's April 2019 stop-sale order for transvaginal POP devices included Xenform, a bovine-derived graft, as well as synthetic products.[1][2]
Material and handling
The reviewed Peri-Guard IFU describes tissue stored wet in a water/propylene-oxide solution, with glutaraldehyde processing and subsequent sterilization. It requires immersion and agitation in 500 mL of sterile normal saline for at least three minutes before use. This is a product-specific instruction, not a generic preparation method for all bovine grafts. Bovine-material hypersensitivity is a contraindication; reuse and resterilization are prohibited. Fibrosis, inflammation and calcification remain possible despite processing.[1]
Crosslinking changes durability and remodeling, but neither “crosslinked” nor “non-crosslinked” guarantees incorporation, freedom from infection or preservation of organ function. Use the actual package IFU and confirm its indication, preparation and fixation requirements. Historical papers may describe preparations differently from currently distributed products.
Peyronie's disease
Bovine pericardium is one of several materials used in tunical lengthening procedures. Current EAU guidance does not identify one graft material as best. Patient selection, baseline erectile function, the deformity and the operative technique determine the tradeoff between straightening and risks such as erectile dysfunction, recurrent curvature, sensory change and shortening. See the Peyronie's surgical atlas for procedure selection.[3]
Two historical cohorts illustrate the limits of material-specific claims:
| Source | What was observed | What it does not establish |
|---|---|---|
| Romero Otero et al., prospective single-surgeon series: 43 treated, 41 followed; mean 14 months | Complete straightening in 33/41 (80.5%); 31/41 reported intercourse without further ED treatment; 35/41 would choose surgery again. One glans ischemic event, one edema event and two sensory-loss events occurred. | The cohort was highly selected: age under 55, good baseline erectile function and limited vascular risk. Plaque excision, occasional plication and postoperative rehabilitation accompanied the graft. It does not show universal erectile preservation, superior material performance or a significant length gain.[4] |
| Caraceni et al., Xenform series: 28 treated, 16 assessed at one year or longer | Complete straightening in 75% of those assessed; ED in 25% and reduced glans sensitivity in 43.8%; one hematoma required surgical revision. | The outcomes are not based on all 28 treated patients. A small uncontrolled study cannot establish low complication risk or equivalence to other grafts.[5] |
Uncontrolled pooled success rates should not be used to rank bovine pericardium above or below oral mucosa, porcine matrices or collagen patches: populations, operations, outcome definitions and follow-up differ.[3]
Pelvic organ prolapse and continence surgery
Transvaginal POP repair requires separate regulatory and clinical interpretation. Xenform is not a currently authorized US transvaginal POP option. The FDA's subsequent review of its completed postmarket study continued to find an unfavorable benefit–risk profile for transvaginal POP use.[2]
- A 94-patient randomized anterior-repair trial found no statistically significant improvement from bovine collagen reinforcement; 72 patients were assessed at one year and 59 at two years. This was not proof of equal efficacy or safety.[6]
- The 2022 Xenform study was nonrandomized, comparing 228 graft patients with 485 native-tissue repairs using propensity adjustment. At 36 months, reported composite success was 83.6% versus 80.5%. It met its specified noninferiority margins, but this does not demonstrate superiority or erase the FDA's regulatory conclusion. Serious adverse events were reported in 12/228 versus 13/485, and exposure in 2/228 graft patients.[7]
- The six-year PROSPECT follow-up found no symptom benefit from adding biological graft to primary vaginal wall repair. It studied a group of biological materials, not a randomized comparison proving the performance of a particular bovine brand; 65% returned six-year questionnaires and there was no examination at that follow-up.[8]
These vaginal-repair findings do not determine the results of abdominal sacrocolpopexy or a continence sling. Likewise, studies of porcine dermis/SIS slings or human cadaveric pericardium should not be presented as bovine-graft evidence. See Porcine Acellular Collagen Matrix and Autologous Rectus Fascia for those separate materials.
Urethral and bladder reconstruction
Current evidence does not establish bovine matrices as a routine substitute for oral mucosa in urethroplasty or for bowel in augmentation cystoplasty. EAU guidance favors oral mucosa when available and advises against cell-free tissue-engineered grafts in extensive spongiofibrosis, after failed urethroplasty or for strictures longer than 4 cm; this is a weak recommendation, not a bovine-product license or a guarantee below that length.[9]
Animal incorporation or histology is not equivalent to durable human urinary function. For example, one canine urethral-patch experiment reported fistulas in 24/30 animals. That result concerns its specific experimental preparation and operation; it does not estimate human risk for every bovine material.[10] Small bladder-repair reports and regenerative experiments remain insufficient to support routine bovine-graft augmentation.
See also: Porcine SIS, Decellularized ECM, and Polypropylene Mesh.
References
1. Baxter. Peri-Guard Repair Patch: instructions for use. MS0742145B, August 3, 2021; English section of the manufacturer-hosted document. IFU.
2. US Food and Drug Administration. FDA's activities: urogynecologic surgical mesh. April 2019 action and subsequent completed postmarket-study assessments. FDA.
3. European Association of Urology. Sexual and Reproductive Health Guidelines 2026: penile curvature, surgical treatment. Guideline.
4. Romero Otero J, García Gómez B, Medina Polo J, et al. Use of a lyophilized bovine pericardium graft to repair tunical defect in patients with Peyronie's disease: experience in a clinical setting. Asian J Androl. 2017;19:316–320. doi:10.4103/1008-682X.171572.
5. Caraceni E, Leone L, Utizi L, Marronaro A. Use of a non-cross-linked xenograft (Xenform) in surgical treatment of Peyronie's disease. Urology. 2016;95:103–107. doi:10.1016/j.urology.2016.05.040.
6. Guerette NL, Peterson TV, Aguirre OA, et al. Anterior repair with or without collagen matrix reinforcement: a randomized controlled trial. Obstet Gynecol. 2009;114:59–65. doi:10.1097/AOG.0b013e3181a81b41.
7. Lipetskaia L, Gonzalez RR, Wu JM, et al. Thirty-six-month prospective study of transvaginal bovine graft vs native tissue repair for the treatment of pelvic organ prolapse. Urology. 2022;167:234–240. doi:10.1016/j.urology.2022.06.003.
8. Reid F, Aucott L, Glazener C, et al. PROSPECT: 4- and 6-year follow-up of a randomised trial of surgery for vaginal prolapse. Int Urogynecol J. 2023;34:299–309. doi:10.1007/s00192-022-05308-0.
9. European Association of Urology. Urethral Strictures Guidelines 2026: tissue transfer. Guideline.
10. Lara RC, Lucon AM, Arap S. Urethroplasty using a bovine pericardium graft: an experimental study using normal urethras from dogs. Braz J Med Biol Res. 2004;37:327–331. doi:10.1590/S0100-879X2004000300006.